PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Xiangju Capsules (containing P. strobilacea infructescence) show efficacy and safety in clinical treatment [PMID:35850854]
Fruit extract and ellagic acid increased type I collagen mRNA expression; clinical measurements showed a statistically significant difference (p < 0.05) [PMID:20587350]
Oral supplement of leaf extract (20-100 mg/kg) protected the brain via antioxidative properties [PMID:31949989]
Leaf extract inhibited TNF-alpha production and bone loss induced by Porphyromonas gingivalis-derived LPS [PMID:30172945]
Topical application of extract promoted hair growth in male C57BL/6 mice [PMID:25320710]
Evidence summary
PubMed sources
- 1.PMID: 38443357 (2024) — Chromosome-level genome assembly of Platycarya strobilacea. · Scientific data
- 2.PMID: 34387671 (2022) — Platycarya strobilacea Sieb. et Zucc.: a review of its traditional uses, botany, phytochemistry, pharmacology and toxicology. · The Journal of pharmacy and pharmacology
- 3.PMID: 33419270 (2020) — New Cyclic Diarylheptanoids from Platycarya strobilacea. · Molecules (Basel, Switzerland)
- 4.PMID: 31949989 (2019) — Platycarya strobilacea leaf extract protects mice brain with focal cerebral ischemia by antioxidative property. · Anatomy & cell biology
- 5.PMID: 34299409 (2021) — Ellagitannin Digestion in Moth Larvae and a New Dimeric Ellagitannin from the Leaves of Platycarya strobilacea.